Eleven startup businesses recently graduated from the Edge, a community growth business accelerator founded late last year by Frederick Innovative Technology Center, Inc. (FITCI) in collaboration with Frederick National Laboratory for Cancer Research and many community partners.
The national laboratory formed dozens of new collaborations, bringing in millions of dollars in partner contributions to enable vital cancer and HIV/AIDS research.
The Frederick National Laboratory for Cancer Research is taking its science to new heights – with an experiment rocketing into orbit around the Earth. The aim is to grow protein crystals in the weightlessness of space.
A new chemical test available through the Frederick National Laboratory for Cancer Research could accelerate human papillomavirus (HPV) research by detecting 40 percent more HPVs than the current gold standard research test.
Drug developers now have access to a shared analytical technology, developed and provided by the Frederick National Laboratory, that helps fine-tune nanomedicine formulations and overcomes a key hurdle on the path toward Food and Drug Administration approval of effective new therapies and generic versions of nanomedicines.
The Frederick National Laboratory and the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) will work under a formal collaboration to evaluate the effectiveness of new compounds that might be used to enhance the immune response to vaccines.
The Frederick National Laboratory has entered into a new partnership with Fred Hutchinson Cancer Research Center that if successful, could improve current methods of donor selection and thereby make lifesaving transplant procedures more readily available for patients with leukemia, multiple myeloma, and other disorders.
The Frederick National Laboratory is part of an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources, and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies.
More than 100,000 newly diagnosed cases of cancer each year in the United States are subsequently linked to mutations in the KRAS protein. In response to this urgent problem, a new partnership agreement involving the Frederick National Laboratory could help identify significant therapeutic opportunities to target these types of cancers.